Safety and Efficacy of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naïve...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter N. Nagata
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors N. Nagata1, H. Mishima2, S. Kurosawa3, K. Oba4, J. Sakamoto5
  • 1Kitakyushu General Hospital, Kitakyushu, Fukuoka, Japan, /
  • 2Aichi Medical University, Nagakute, Aichi, Japan, /
  • 3Takeda Pharmaceutical Company ltd., Chuo-ku, Tokyo, Japan, /
  • 4University of Tokyo, Bunkyo-ku, Tokyo, Japan, /
  • 5/


In Japan, oxaliplatin/5-FU/leucovorin (mFOLFOX6) is the most frequent first-line chemotherapy backbone for metastatic colorectal cancer (mCRC). However, peripheral nerve disorders caused by oxaliplatin (OXA), part of mFOLFOX6 therapy, decrease patients’ quality of life. For patients who discontinue OXA after taking it for a certain period with no peripheral nerve disorders, OXA re-introduction at a later stage may be an option. This \"stop and go\" OXA approach with 5-FU/leucovorin maintenance was explored in OPTIMOX-1 study and showed similar efficacy as with continuous OXA administration. The present study evaluates the safety and efficacy of mFOLFOX6 plus panitumumab induction with 5-FU/leucovorin+ panitumumab maintenance in first line mCRC patients.